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cardiometabolic profile among patients hospitalized for acute 
myocardial infarction
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Introduction: Previous studies showed an increased likelihood and risk of acute myocardial infarction (AMI) and 
hospitalizations for cardiovascular events among patients exposed to chronic use of proton pump inhibitors (PPIs).1-3 
In this study we aimed to compare parameters reflecting disease burden and cardiometabolic profile among patients 
treated for AMI with respect to the chronic exposure to PPIs. 
Patients and Methods: Data of 143 adult consecutive patients hospitalized for ST-elevation myocardial infarction 
(STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) during the 2019-2020 period were analyzed. 
All continuous variables had a normal distribution. 
Results: The mean age was 64.8 ± 11.3 years and 
79.7% were men. Two-thirds (65.7%) of patients had 
STEMI while 34.3% had NSTEMI. The mean GRACE 
score in the whole cohort was 117 ± 26 points while 
12.6% of patients were at high risk of in-hospital 
death, after adjustment for the ACS type. A total 
of 19 IPP+ patients were identified. Patients in the 
IPP+ group were significantly older and had a high-
er prevalence of NSTEMI compared to IPP- group 
while both groups did not significantly differ in 
terms of sex, body mass index, waist-to-hip ratio, 
the mean number of diseased vessels at angiogra-
phy, and left ventricular ejection fraction. Patient 
IPP+ group had a significantly higher high-sensi-
tivity cardiac troponin I rise from 1st to 2nd measure-
ment compared to IPP- group (4726 ± 5938 vs. 2554 
± 3480 ng/L, p=0.025, Table 1). Furthermore, C-reac-
tive protein, blood glucose, and serum creatinine 
levels at admission were significantly higher in 
IPP+ vs. the IPP- group. Finally, patients in the IPP+ 
group had a significantly higher risk of in-hospital 
and 6-month post-discharge death compared to 
IPP- group, as adjudicated by the GRACE score (132 
± 23 vs. 114 ± 26 points, p=0.008). 
Conclusions: Our study showed that AMI patients 
with chronic exposure to IPPs are older, mostly 
male, and tend to present with NSTEMI. These 
patients exhibit a larger magnitude of myocardial 
injury and systemic inflammation accompanied 
by worse renal function, and also seem to be at an 
increased risk of poor in-hospital and post-discharge outcomes. However, potential confounding of underlying co-
morbidities and age must be taken into account when interpreting these results.
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TABLE 1. Comparison of consecutive patients with acute myocardial infarction exposed 
to chronic inhibitor of proton pump (Ipp) use (Ipp+ group) with those not exposed (Ipp-group).
Variable IPP+ group (N=19) IPP- group (N=124) p-value
Age, years 71.9 ± 9.6 63.3 ± 11.2 0.003*
Body mass index, kg/m2 26.2 ± 1.7 27.3 ± 3.4 0.201
Waist-to-hip ratio 1.03 ± 0.07 1.12 ± 0.88 0.644
Male sex 64.7% 81.9% 0.100
NSTEMI as a type of ACS 47.4% 33.1% 0.224
Mean Killip class 1.11 ± 0.33 1.10 ± 0.40 0.890
Mean number of diseased vessels 1.20 ± 0.44 1.17 ± 0.50 0.823
Left ventricular ejection fraction, % 50.8 ± 12.7 52.1 ± 9.8 0.656
Δcardiac Troponin I value, ng/L¶ 4726 ± 5938 2554 ± 3480 0.025*
C-reactive protein, mg/L 27.4 ± 48.5 11.7 ± 20.0 0.015*
Glucose, mmol/L 9.5 ± 4.8 7.7 ± 3.0 0.037*
Creatinine, μmol/L 110 ± 56 89 ± 26 0.012*
Sodium, mmol/L 138 ± 2.9 137 ± 3.0 0.146
Potassium, mmol/L 4.04 ± 0.43 4.08 ± 0.40 0.724
GRACE score, points 132 ± 23 114 ± 26 0.008*
ACS-acute coronary syndrome; AMI-acute myocardial infarction; GRACE-Global Registry of Acute Coronary 
Events; NSTEMI-Non-ST-segment elevation myocardial infarction.
*result significant at a two-tailed p-value <0.05
¶high-sensitivity cardiac troponin I assay, mean difference from 1st to 2nd measurement
